19th Ave New York, NY 95822, USA
Join Now

Molecular Oncology Group

Portfolio Item Molecular Oncology Group
CORE TECHNOLOGIES

VHIO’s Molecular Oncology Group applies state-of-the-art tissue-based technologies to basic, translational, and clinical research with a clear focus on developing and validating novel tumor biomarkers for precision medicine in oncology.

Together with VHIO’s Cancer Genomics Group (PI Ana Vivancos), Oncology Data Science – ODysSey Group (PI Rodrigo Dienstmann), and our Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, (directed by Elena Garralda), we participate in our in-house Molecular Prescreening Program. We molecularly profile over 1,100 patients each year as candidates for enrolment in early phase clinical trials at the UITM – CaixaResearch.

Our group also serves as one of VHIO’s Core Technology Platforms and our laboratory is therefore key to VHIO’s translational research lines and programs. We actively participate in all projects involving the use of human tissue collected from patients. These include biomarker analyses for patient stratification and inclusion in clinical trials, digital pathology, tissue banking, and the development of primary patient-derived xenograft (PDX) models. Our contributions are reflected by several high-impact factor collaborative papers published throughout 2022.

Additionally, we continue to work independently and in partnership to decipher the impact of the microbiome in colorectal cancer development and progression. In particular, we are investigating the tumor-associated microbiota at a spatial resolution by developing bacteria-specific probes within the OPTIMISTICC Grand Challenge project funded by Cancer Research UK (CRUK).

We are also leading the FUSOMAP, a 3-year project funded by the Mutua Madrileña Foundation and Instituto de Salud Carlos III – ISCIII (Carlos III Health Institute), to develop microbiota-based diagnostic and prognostic models by mapping intratumoral Fusobacterium and associated gut microbiota in early-stage colorectal cancer. Lastly, we are studying the consequences of Sars-Cov-2 infection on the microbiome of cancer patients and how it impacts on clinical outcome (project funded by La Marató TV3).

As a Core Facility, we have provided support for 394 clinical studies conducted at Vall d’Hebron, representing approximately 70% of all currently open trials at our Institute. Our involvement in these trials includes the coordination of sample collection, storage and shipment, developing and running multiple assays for real-time patient inclusion, as well as pharmacodynamic monitoring and dose finding.

In 2022, we performed approximately 3000 molecular determinations on samples for patient inclusion in clinical trials, and over 30,000 tests to support basic and translation research. We have also served as the central laboratory of choice for several international studies, and successfully maintained the prestigious ISO15189 accreditation that endorses quality and competence.

Paolo G. Nuciforo
Group Leader
Biosketch

Research Lines

  • Discovery and validation of novel biomarkers using tissue-based technologies.
  • Identification of targetable alterations as part of VHIO’s Molecular Prescreening Program
  • Application of molecular pathology strategies to support early clinical drug development programs.
  • Resolve spatial interaction of tumor-associated microbiota, tumor cells, and immune cells in the tumor microenvironment.
  • Multiplexed immunohistochemistry and digital image analysis for high-resolution, single cell, tissue biomarker contexture analyses.
  • Better define molecular target epidemiology to render treatment strategies more precise.
  • Act as a central and local laboratory in clinical trials.
  • Serve as a Core Facility for VHIO research programs.

Figure: A) KiQuant workflow. B) A tumor core sequentially stained with Ki67 (top) and Pan-Keratin (middle). The two stainings are aligned into a single virtual digital image (bottom). Tumor region of interest are automatically identified by the Pan-Keratin-positive brown areas (dotted orange line). Green and red cells represent Ki67-negative and -positive nuclei, respectively.

Team

Group Leader
Paolo G. Nuciforo
Attending Physicians
Roberta Fasani
Sara Simonetti
Siarhei Mauchanski,
Laboratory Supervisor
Jose Antonio Jiménez
Laboratory Assistant
Mª Ángeles Diaz
Post-Doctoral Fellow
Francisca Gallego
PhD Students
Garazi Serna
Stefania Napoli
Technicians
Lidia Alonso
Xavier Guardia
Paola Martinez
Lidia Sánchez
Gertrudis Sánchez
César Sevillano
Antonella Cogoni
Luis Garcia
Pau Taltavull
Margarita Gonzalez

Publications

Most relevant scientific publications

  • Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos-Coelho JL, Gil-Gil MJ, Bermejo B, Pratt DA, Ciruelos EM, Villagrasa P, Wongchenko MJ, Petricoin EF, Oliveira M, Isakoff SJ. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Mar 1;28(5):993-1003. doi: 10.1158/1078-0432.CCR-21-2498. (Co-Authorship). Original publication.
  • Senís E, Esgleas M, Najas S, Jiménez-Sábado V, Bertani C, Giménez-Alejandre M, Escriche A, Ruiz-Orera J, Hergueta-Redondo M, Jiménez M, Giralt A, Nuciforo P, Albà MM, Peinado H, Del Toro D, Hove-Madsen L, Götz M, Abad M. TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics. Front Cell Dev Biol. 2021 Dec 31;9:747667. doi: 10.3389/fcell.2021.747667. eCollection 2021. (Co-Authorship). Original publication.
  • Verdaguer H, Saurí T, Acosta DA, Guardiola M, Sierra A, Hernando J, Nuciforo P, Miquel JM, Molero C, Peiró S, Serra-Camprubí Q, Villacampa G, Aguilar S, Vivancos A, Tabernero J, Dienstmann R, Macarulla T. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma. Clin Cancer Res. 2022 Apr 14;28(8):1662-1671. doi: 10.1158/1078-0432.CCR-21-2384. (Co-Authorship). Original publication.
  • Grussu F, Bernatowicz K, Casanova-Salas I, Castro N, Nuciforo P, Mateo J, Barba I, Perez-Lopez R. Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4T imaging, and histology. Magn Reson Med. 2022 Jul;88(1):365-379. doi: 10.1002/mrm.29174. Epub 2022 Feb 18. (Co-Authorship). Original publication.
  • Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261. doi: 10.1038/s43018-022-00332-x. Epub 2022 Feb 24. (Co-Authorship). Original publication.
  • Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O’Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409. (Co-Authorship). Original publication.
  • Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink-Clements C, Zondag-van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan-Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat Cancer. 2022 Apr;3(4):418-436. doi: 10.1038/s43018-022-00359-0. Epub 2022 Apr 25. (Co-Authorship). Original publication.
  • Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. J Natl Cancer Inst. 2022 Dec 8;114(12):1720-1727. doi: 10.1093/jnci/djac126. (Co-Authorship). Original publication.
  • Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, Freimoser-Grundschober A, Cuartas I, Martínez-Moreno A, Martínez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia-Reyes X, Fahrni L, Pöschinger T, Steinhart V, Richard M, Briner S, Mueller J, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, González J, Nuciforo P, Carles J, Vieito M, Tabernero J, Umaña P, Seoane J. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther. 2022 Oct 7;21(10):1499-1509. doi: 10.1158/1535-7163.MCT-22-0201. (Co-Authorship). Original publication.
  • Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V.High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+breast cancer. Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. (Co-Authorship). Original publication.
  • Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600Emetastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170. doi: 10.1038/s41591-022-01976-z. Epub 2022 Sep 12. (Co-Authorship). Original publication.
  • Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoue-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Sci Rep. 2022 Nov 9;12(1):19055. doi: 10.1038/s41598-022-21448-1. (Co-Authorship). Original publication.
  • Boix O, Martinez M, Vidal S, Giménez-Alejandre M, Palenzuela L, Lorenzo-Sanz L, Quevedo L, Moscoso O, Ruiz-Orera J, Ximénez-Embún P, Ciriaco N, Nuciforo P, Stephan-Otto Attolini C, Albà MM, Muñoz J, Tian TV, Varela I, Vivancos A, Ramón Y Cajal S, Muñoz P, Rivas C, Abad M. pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation. Nat Commun. 2022 Nov 11;13(1):6840. doi: 10.1038/s41467-022-34529-6. (Co-Authorship). Original publication.
  • Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. Clin Cancer Res. 2023 Jan 17;29(2):432-445. doi: 10.1158/1078-0432.CCR-22-2551. (Co-Authorship). Original publication.
  • Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou CM, Carey LA.Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.JAMA Oncol. 2023 Jan 5:e226288. doi: 10.1001/jamaoncol.2022.6288. Online ahead of print. (Co-Authorship). Original publication.
  • Élez E, Mulet-Margalef N, Sanso M, Ruiz-Pace F, Mancuso FM, Comas R, Ros J, Argilés G, Martini G, Sanz-Garcia E, Baraibar I, Salvà F, Noguerido A, Cuadra-Urteaga JL, Fasani R, Garcia A, Jimenez J, Aguilar S, Landolfi S, Hernández-Losa J, Braña I, Nuciforo P, Dienstmann R, Tabernero J, Salazar R, Vivancos A. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. Int J Mol Sci. 2022 Dec 21;24(1):118. doi: 10.3390/ijms24010118. (Co-Authorship). Original publication.
  • Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart M, Di Cosimo S, de Azambuja E, Demeestere I.Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. J Natl Compr Canc Netw. 2023 Jan;21(1):33-41.e16. doi: 10.6004/jnccn.2022.7065. (Co-Authorship). Original publication.
  • Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023 Mar;181:92-101. doi: 10.1016/j.ejca.2022.12.020. Epub 2022 Dec 27. (Co-Authorship). Original publication.
  • Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023 Mar;181:92-101. Epub 2022 Dec 27.
  • Borgognone A, Serna G, Noguera-Julian M, Alonso L, Parera M, Català-Moll F, Sanchez L, Fasani R, Paredes R, Nuciforo P. Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues. Cancers (Basel). 2021 Oct 29;13(21):5421.
  • Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021 Mar 19;5(1):23.
  • Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci. 2021 Feb 1;22(3):1446.
  • Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. J Clin Invest. 2021 Mar 15;131(6):e145427.
  • Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P.NPJ Precis Oncol. 2021 Mar 19;5(1):23. doi: 10.1038/s41698-021-00163-6.
  • Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P.J Clin Invest. 2021 Mar 15;131(6):e145427. doi: 10.1172/JCI145427.
  • Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, Comas R, Jimenez J, Elez E, Bullman S, Tabernero J, Capdevila J, Dienstmann R, Nuciforo P. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366-1375.
  • Serna G, Simonetti S, Fasani R, Pagliuca F, Guardia X, Gallego P, Jimenez J, Peg V, Saura C, Eppenberger-Castori S, Ramon Y Cajal S, Terracciano L, Nuciforo P. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. Breast. 2020 Oct;53:102-110.
  • Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González- Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precis Oncol. 2020 May 14;4:PO.19.00398.
  • Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2019 Nov 1;30(11):1843.
  • Vivancos A, Élez E, Salazar R. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime? Ann Oncol.29: 532-534.
  • Capdevila J,Mayor R; Mancuso FF, Iglesias C; Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez C, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol.29: 1454-1460.
  • Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P,Mancuso F, Serra V, Vivancos A. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst.110: 914-917.
  • Puig I, Tenbaum SP, Chicote I, Arqués O,Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P,Seoane J,Recio JA, Vivancos A,Dienstmann R,Tabernero J,Palmer HG.TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest.128: 3887-3905.
  • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S,Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN; Kristel P, de Bustos L, Guzman M,Rodriguez O, Grueso J, Montalban G, Caratú G,Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O; O’Connor MJ, Balmaña J,Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol.29: 1203-1210. IF: 13,926
  • Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, Lopez-Bigas N, Ramón Y Cajal S, Vieito M, Carles J, Tabernero J,Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.Clin Cancer Res.24: 2812-2819.

All publications

  • Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci. 2021 Feb 1;22(3):1446.
  • Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, Seoane J. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nat Commun. 2021 Mar 8;12(1):1503.
  • Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. J Clin Invest. 2021 Mar 15;131(6):e145427.
  • Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021 Mar 19;5(1):23.
  • Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2021 Mar 31:djab057.
  • Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer. 2021 Apr;124(9):1581-1591.
  • Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887-900.
  • Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119.
  • De Mattos-Arruda L, Cortes J, Blanco-Heredia J, Tiezzi DG, Villacampa G, Gonçalves-Ribeiro S, Paré L, Souza CA, Ortega V, Sammut SJ, Cusco P, Fasani R, Chin SF, Perez-Garcia J, Dienstmann R, Nuciforo P, Villagrasa P, Rubio IT, Prat A, Caldas C. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ Breast Cancer. 2021 Jun 7;7(1):73
  • Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507-2543. doi: 10.1002/1878-0261.13078
  • Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618.
  • Borgognone A, Serna G, Noguera-Julian M, Alonso L, Parera M, Català-Moll F, Sanchez L, Fasani R, Paredes R, Nuciforo P. Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues. Cancers (Basel). 2021 Oct 29;13(21):5421.
  • Martinez-Marti A, Felip E, Mancuso FM, Caratú G, Matito J, Nuciforo P, Sansano I, Diaz-Mejia N, Cedrés S, Callejo A, Iranzo P, Pardo N, Miquel JM, Navarro A, Vivancos A, Sansó M. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. Br J Cancer. 2021 Nov;125(11):1561-1569. doi: 10.1038/s41416-021-01558-9.
  • Wurm M, Schaaf O, Reutner K, Ganesan R, Mostböck S, Pelster C, Böttcher J, de Andrade Pereira B, Taubert C, Alt I, Serna G, Auguste A, Stadermann KB, Delic D, Han F, Capdevila J, Nuciforo PG, Kroe-Barrett R, Adam PJ, Vogt AB, Hofmann I. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Mol Cancer Ther. 2021 Nov;20(11):2250-2261.
  • Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, Nuciforo P, Canes J, Paré L, Dueñas M, Vidal M, Cejalvo JM, Perelló A, Llommbard-Cussac A, Dorca J, Montaño A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 2021 Nov 4;11:744112.
  • Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clin Cancer Res. 2021 Nov 15;27(22):6156-6163.
  • Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, Prat A, Cortés J. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. NPJ Breast Cancer. 2021 Nov 25;7(1):145.
  • Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clin Cancer Res. 2021 Dec 1;27(23):6307-6313.
  • El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1;7(1):150.
  • Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos-Coelho JL, Gil-Gil MJ, Bermejo B, Pratt DA, Ciruelos EM, Villagrasa P, Wongchenko MJ, Petricoin EF, Oliveira M, Isakoff SJ. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Dec 14. doi: 10.1158/1078-0432.CCR-21-2498. Epub ahead of print. PMID: 34907082.
  • Senís E, Esgleas M, Najas S, Jiménez-Sábado V, Bertani C, Giménez-Alejandre M, Escriche A, Ruiz-Orera J, Hergueta-Redondo M, Jiménez M, Giralt A, Nuciforo P, Albà MM, Peinado H, Del Toro D, Hove-Madsen L, Götz M, Abad M. TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics. Front Cell Dev Biol. 2021 Dec 31;9:747667.
  • Chic, Nuria ; Luen, Stephen J ; NUCIFORO, PAOLO GIOVANNI; Salgado, Roberto ; Fumagalli, Debora ; Hilbers, Florentine ; Wang, Yingbo ; de Azambuja, Evandro ; Làng, István ; DI COSIMO, SERENA; SAURA MANICH, CRISTINA; Huober, Jens ; PRAT APARICIO, ALEIX; Loi, Sherene. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.1093/jnci/djab057
  • Frigola, Joan; NAVARRO MENDIVIL, ALEJANDRO; Carbonell, Caterina ; Callejo, Ana ; Iranzo, Patricia ; CEDRES PEREZ, SUSANA; MARTINEZ MARTI, ALEXANDRE; PARDO ARANDA, NURIA; Saoudi-Gonzalez, Nadia ; Martinez, Debora ; JIMENEZ, JOSE; Sansano, Irene ; MANCUSO, FRANCESCO MATTIA; NUCIFORO, PAOLO GIOVANNI; Montuenga, Luis M ; Sánchez-Cespedes, Montse ; PRAT APARICIO, ALEIX; VIVANCOS PRELLEZO, ANA; FELIP FONT, ENRIQUETA; AMAT FERRER, RAMON. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. MOLECULAR ONCOLOGY. 2021 April. 10.1002/1878-0261.12891
  • LIGERO HERNANDEZ, MARTA; Garcia-Ruiz, Alonso ; VIAPLANA DONATO, CRISTINA; VILLACAMPA JAVIERRE, GUILLERMO; Raciti, Maria V ; Landa, Jaid ; MATOS GARCIA, IGNACIO; MARTIN LIBERAL, JUAN JESUS; OCHOA DE OLZA AMAT, MARIA; HIERRO CARBO, CINTA; MATEO VALDERRAMA, JOAQUIN; Gonzalez, Macarena ; MORALES BARRERA, RAFAEL; SUAREZ RODRIGUEZ, CRISTINA; RODON AHNERT, JORDI; ELEZ FERNANDEZ, MARIA ELENA; BRAÑA GARCIA, IRENE; MUÑOZ COUSELO, EVA; OAKNIN BENZAQUEN, ANA MAZALTOB; FASANI, ROBERTA; NUCIFORO, PAOLO GIOVANNI; Gil, Debora ; RUBIO, ISABEL TERESA; SEOANE SUAREZ, JOAN; FELIP FONT, ENRIQUETA; Escobar, Manuel ; TABERNERO CATURLA, JOSEP; CARLES GALCERAN, JOAN; DIENSTMANN, RODRIGO; GARRALDA CABANAS, ELENA; PEREZ LOPEZ, RAQUEL. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 April. 10.1148/radiol.2021200928
  • RUBIO PEREZ, CARLOTA; Planas-Rigol, Ester ; Trincado, Juan L ; BONFILL TEIXIDOR, ESTER; ARIAS PIÑEIRO, ALEXANDRA; Marchese, Domenica ; Moutinho, Catia ; SERNA ALONSO, GARAZI; Pedrosa, Leire ; IURLARO, RAFFAELLA; Martínez-Ricarte, Francisco ; ESCUDERO MONREAL, LAURA; Cordero, Esteban ; Cicuendez, Marta ; Ruiz, Sara ; Parra, Genís ; NUCIFORO, PAOLO GIOVANNI; Gonzalez, Josep ; Pineda, Estela ; Sahuquillo, Juan ; TABERNERO CATURLA, JOSEP; Heyn, Holger ; SEOANE SUAREZ, JOAN. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. NATURE COMMUNICATIONS. 2020 March. 10.1038/s41467-021-21789-x
  • Oliva, Marc ; MULET MARGALEF, NURIA; OCHOA DE OLZA AMAT, MARIA; Napoli, Stefania ; Mas, Joan ; Laquente, Berta ; Alemany, Laia ; Duell, Eric J ; NUCIFORO, PAOLO GIOVANNI; Moreno, Victor. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Tumor-Associated Microbiome: Where Do We Stand?. 2021 February. 10.3390/ijms22031446
  • Hudecek, J. ; Voorwerk, L. ; van Seijen, M. ; Nederlof, I. ; de Maaker, M. ; van den Berg, J. ; van de Vijver, K.K. ; Sikorska, K. ; Adams, S. ; Demaria, S. ; Viale, G. ; Nielsen, T.O. ; Badve, S.S. ; Michiels, S. ; Symmans, W.F. ; Sotiriou, C. ; Rimm, D.L. ; Hewitt, S.M. ; Denkert, C. ; Loibl, S. ; Loi, S. ; Bartlett, J.M.S. ; Pruneri, G. ; Dillon, D.A. ; Cheang, M.C.U. ; Tutt, A. ; Hall, J.A. ; Kos, Z. ; Salgado, R. ; Kok, M. ; Horlings, H.M. ; Hyytiäinen, A. ; Hida, A.I. ; Thompson, A. ; Lefevre, A. ; Lazar, A.J. ; Gown, A. ; Lo, A. ; Sapino, A. ; Madabhushi, A. ; Moreira, A. ; Richardson, A. ; Vingiani, A. ; Beck, A.H. ; Bellizzi, A.M. ; Guerrero, A. ; Grigoriadis, A. ; Ehinger, A. ; Garrido-Castro, A. ; Vincent-Salomon, A. ; Laenkholm, A.-V. ; Sharma, A. ; Cimino-Mathews, A. ; Srinivasan, A. ; Acs, B. ; Singh, B. ; Calhoun, B. ; Haibe-Kans, B. ; Solomon, B. ; Thapa, B. ; Nelson, B.H. ; Gallas, B.D. ; Castaneda, C. ; Ballesteros-Merino, C. ; Criscitiello, C. ; Boeckx, C. ; Colpaert, C. ; Quinn, C. ; Chennubhotla, C.S. ; Swanton, C. ; Solinas, C. ; Hiley, C. ; Drubay, D. ; Bethmann, D. ; Moore, D.A. ; Larsimont, D. ; Sabanathan, D. ; Peeters, D. ; Zardavas, D. ; Höflmayer, D. ; Johnson, D.B. ; Thompson, E.A. ; Brogi, E. ; Perez, E. ; ElGabry, E.A. ; Stovgaard, E.S. ; Blackley, E.F. ; Roblin, E. ; Reisenbichler, E. ; Bellolio, E. ; Balslev, E. ; Chmielik, E. ; Gaire, F. ; Andre, F. ; Lu, F.-I. ; Azmoudeh-Ardalan, F. ; Rojo, F. ; Gruosso, T. ; Ciompi, F. ; Peale, F. ; Hirsch, F.R. ; Klauschen, F. ; Penault-Llorca, F. ; Acosta Haab, G. ; Farshid, G. ; van den Eynden, G. ; Curigliano, G. ; Floris, G. ; Broeckx, G. ; Gonzalez-Ericsson ; Koeppen, H. ; Haynes, H.R. ; McArthur, H. ; Joensuu, H. ; Olofsson, H. ; Lien, H.-C. ; Chen, I.-C. ; Cree, I. ; Frahm, I. ; Brcic, I. ; Chan, J. ; Ziai, J. ; Brock, J. ; Wesseling, J. ; Giltnane, J. ; Kerner, J.K. ; Thagaard, J. ; Braybrooke, J.P. ; van der Laak, J.A.W.M. ; Lemonnier, J. ; Zha, J. ; Ribeiro, J. ; Lennerz, J.K. ; Carter, J.M. ; Saltz, J. ; Hartman, J. ; Hainfellner, J. ; Quesne, J.L. ; Juco, J.W. ; Reis-Filho, J. ; Sanchez, J. ; Sparano, J. ; Cucherousset, J. ; Araya, J.C. ; Adam, J. ; Balko, J.M. ; Saeger, K. ; Siziopikou, K. ; Willard-Gallo, K. ; Weber, K. ; Pogue-Geile, K.L. ; Steele, K.E. ; Emancipator, K. ; AbdulJabbar, K. ; El Bairi, K. ; Blenman, K.R.M. ; Allison, K.H. ; Korski, K. ; Pusztai, L. ; Comerma, L. ; Buisseret, L. ; Cooper, L.A.D. ; Shi, L. ; Kooreman, L.F.S. ; Molinero, L. ; Estrada, M.V. ; Lacroix-Triki, M. ; Al Bakir, M. ; Sebastian, M.M. ; van de Vijver, M. ; Balancin, M.L. ; Dieci, M.V. ; Mathieu, M.-C. ; Rebelatto, M.C. ; Piccart, M. ; Hanna, M.G. ; Goetz, M.P. ; Preusser, M. ; Khojasteh, M. ; Sanders, M.E. ; Regan, M.M. ; Barnes, M. ; Christie, M. ; Misialek, M. ; Ignatiadis, M. ; van Bockstal, M. ; Castillo, M. ; Amgad, M. ; Harbeck, N. ; Tung, N. ; Laudus, N. ; Sirtaine, N. ; Burchardi, N. ; Ternes, N. ; Radosevic-Robin, N. ; Gluz, O. ; Grimm, O. ; NUCIFORO, PAOLO GIOVANNI; Jank, P. ; Gonzalez-Ericsson, P. ; Kirtani, P. ; Jelinic, P. ; Watson, P.H. ; Savas, P. ; Francis, P.A. ; Russell, P.A. ; Singh, R. ; Kim, R.S. ; Pierce, R.H. ; Hills, R. ; Leon-Ferre, R. ; de Wind, R. ; Shui, R. ; De Clercq, S. ; Leung, S. ; Tabbarah, S. ; Souza, S.C. ; O’Toole, S. ; Swain, S. ; Dudgeon, S. ; Willis, S. ; Ely, S. ; Kim, S.-R. ; Bedri, S. ; Irshad, S. ; Liu, S.-W. ; Goel, S. ; Hendry, S. ; Bianchi, S. ; Bragança, S. ; Paik, S. ; Wienert, S. ; Fox, S.B. ; Luen, S.J. ; Naber, S. ; Schnitt, S.J. ; Sua, L.F. ; Lakhani, S.R. ; Fineberg, S. ; Soler, T. ; Gevaert, T. ; D’Alfonso, T. ; John, T. ; Sugie, T. ; Kurkure, U. ; Bossuyt, V. ; Manem, V. ; Cámara, V.P. ; Tong, W. ; Chen, W. ; Yang, W. ; Tran, W.T. ; Wang, Y. ; Yuan, Y. ; Allory, Y. ; Husain, Z. ; Bago-Horvath, Z. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ breast cancer. 2020 January. 10.1038/s41523-020-0155-1
  • Chic, Nuria ; Luen, Stephen J ; NUCIFORO, PAOLO GIOVANNI; Salgado, Roberto ; Fumagalli, Debora ; Hilbers, Florentine ; Wang, Yingbo ; de Azambuja, Evandro ; Làng, István ; DI COSIMO, SERENA; SAURA MANICH, CRISTINA; Huober, Jens ; PRAT APARICIO, ALEIX; Loi, Sherene. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.  JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2020 January. 10.1093/jnci/djz042
  • CAPDEVILA CASTILLON, JAUME; MATOS GARCIA, IGNACIO; MANCUSO, FRANCESCO MATTIA; Iglesias, Carmela; NUCIFORO, PAOLO GIOVANNI; Zafon, Carles ; GARCIA PALMER, HECTOR; OGBAH, ZIGHEREDA; Muinos, Laura ; HERNANDO CUBERO, JORGE; Villacampa, Guillermo ; Peña, Carol E ; TABERNERO CATURLA, JOSEP; Brose, Marcia S ; Schlumberger, Martin ; VIVANCOS PRELLEZO, ANA. Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. MOLECULAR CANCER THERAPEUTICS. 2020 January. 10.1158/1535-7163.MCT-19-0211
  • Cebrià-Costa, J P ; PASCUAL REGUANT, LAURA; Gonzalez-Perez, A ; Serra-Bardenys, G ; QUEROL PAÑOL, JESSICA; Cosín, M ; Verde, G ; Cigliano, R A ; Sanseverino, W ; Segura-Bayona, S ; Iturbide, A ; Andreu, D ; NUCIFORO, PAOLO GIOVANNI; Bernado-Morales, C ; RODILLA BENITO, VERONICA; ARRIBAS LOPEZ, JOAQUIN VICENTE; Yelamos, J ; de Herreros, A Garcia ; Stracker, T H ; PEIRO SALES, SANDRA. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. 2020 January. 10.1038/s41388-019-0969-1
  • NUCIFORO, PAOLO GIOVANNI; Townend, J. ; SAURA MANICH, CRISTINA; de Azumbaja, E. ; Hilbers, F. ; Manukyants, A. ; Werutsky, G. ; Bliss, J. ; Moebus, V. ; Colleoni, M. ; Aspitia, A.M. ; Di Cosimo, S. ; Van dooren, V. ; Kroep, J. ; Ferro, A. ; Cameron, D. ; Gelber, R. ; Piccart-Gebhart, M. ; Huober, J. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. EUROPEAN JOURNAL OF CANCER. 2020 January. 10.1016/S0959-8049(20)30560-8
  • Amgad, Mohamed ; Stovgaard, Elisabeth Specht ; Balslev, Eva ; Thagaard, Jeppe ; Chen, Weijie ; Dudgeon, Sarah ; Sharma, Ashish ; Kerner, Jennifer K ; Denkert, Carsten ; Yuan, Yinyin ; AbdulJabbar, Khalid ; Wienert, Stephan ; Savas, Peter ; Voorwerk, Leonie ; Beck, Andrew H ; Madabhushi, Anant ; Hartman, Johan ; Sebastian, Manu M ; Horlings, Hugo M ; Hudecek, Jan ; Ciompi, Francesco ; Moore, David A ; Singh, Rajendra ; Roblin, Elvire ; Balancin, Marcelo Luiz ; Mathieu, Marie-Christine ; Lennerz, Jochen K ; Kirtani, Pawan ; Chen, I-Chun ; Braybrooke, Jeremy P ; Pruneri, Giancarlo ; Demaria, Sandra ; Adams, Sylvia ; Schnitt, Stuart J ; Lakhani, Sunil R ; Rojo, Federico ; Comerma, Laura ; Badve, Sunil S ; Khojasteh, Mehrnoush ; Symmans, W Fraser ; Sotiriou, Christos ; Gonzalez-Ericsson, Paula ; Pogue-Geile, Katherine L ; Kim, Rim S ; Rimm, David L ; Viale, Giuseppe ; Hewitt, Stephen M ; Bartlett, John M S ; Penault-Llorca, Frédérique ; Goel, Shom ; Lien, Huang-Chun ; Loibl, Sibylle ; Kos, Zuzana ; Loi, Sherene ; Hanna, Matthew G ; Michiels, Stefan ; Kok, Marleen ; Nielsen, Torsten O ; Lazar, Alexander J ; Bago-Horvath, Zsuzsanna ; Kooreman, Loes F S ; van der Laak, Jeroen A W M ; Saltz, Joel ; Gallas, Brandon D ; Kurkure, Uday ; Barnes, Michael ; Salgado, Roberto ; Hyytiäinen, Aini ; International Immuno-Oncology Biomarker Working Group ; Hida, Akira I ; Thompson, Alastair ; Lefevre, Alex ; Gown, Allen ; Lo, Amy ; Sapino, Anna ; Moreira, Andre ; Richardson, Andrea ; Vingiani, Andrea ; Bellizzi, Andrew M ; Tutt, Andrew ; Guerrero-Zotano, Angel ; Grigoriadis, Anita ; Ehinger, Anna ; Garrido-Castro, Anna C ; Vincent-Salomon, Anne ; Laenkholm, Anne-Vibeke ; Cimino-Mathews, Ashley ; Srinivasan, Ashok ; Acs, Balazs ; Singh, Baljit ; Calhoun, Benjamin ; Haibe-Kans, Benjamin ; Solomon, Benjamin ; Thapa, Bibhusal ; Nelson, Brad H ; Castaneda, Carlos ; Ballesteroes-Merino, Carmen ; Criscitiello, Carmen ; Boeckx, Carolien ; Colpaert, Cecile ; Quinn, Cecily ; Chennubhotla, Chakra S ; Swanton, Charles ; Solinas, Cinzia ; Hiley, Crispin ; Drubay, Damien ; Bethmann, Daniel ; Dillon, Deborah A ; Larsimont, Denis ; Sabanathan, Dhanusha ; Peeters, Dieter ; Zardavas, Dimitrios ; Höflmayer, Doris ; Johnson, Douglas B ; Thompson, E Aubrey ; Brogi, Edi ; Perez, Edith ; ElGabry, Ehab A ; Blackley, Elizabeth F ; Reisenbichler, Emily ; Bellolio, Enrique ; Chmielik, Ewa ; Gaire, Fabien ; Andre, Fabrice ; Lu, Fang-I ; Azmoudeh-Ardalan, Farid ; Gruosso, Forbius Tina ; Peale, Franklin ; Hirsch, Fred R ; Klaushen, Frederick ; Acosta-Haab, Gabriela ; Farshid, Gelareh ; van den Eynden, Gert ; Curigliano, Giuseppe ; Floris, Giuseppe ; Broeckx, Glenn ; Koeppen, Harmut ; Haynes, Harry R ; McArthur, Heather ; Joensuu, Heikki ; Olofsson, Helena ; Cree, Ian ; Nederlof, Iris ; Frahm, Isabel ; Brcic, Iva ; Chan, Jack ; Hall, Jacqueline A ; Ziai, James ; Brock, Jane ; Wesseling, Jelle ; Giltnane, Jennifer ; Lemonnier, Jerome ; Zha, Jiping ; M Ribeiro, Joana ; Carter, Jodi M ; Hainfellner, Johannes ; Quesne, John Le ; Juco, Jonathan W ; Reis-Filho, Jorge ; van den Berg, Jose ; Sanchez, Joselyn ; Sparano, Joseph ; Cucherousset, Joël ; Araya, Juan Carlos ; Adam, Julien ; Balko, Justin M ; Saeger, Kai ; Siziopikou, Kalliopi ; Willard-Gallo, Karen ; Sikorska, Karolina ; Weber, Karsten ; Steele, Keith E ; Emancipator, Kenneth ; El Bairi, Khalid ; Blenman, Kim R M ; Allison, Kimberly H ; van de Vijver, Koen K ; Korski, Konstanty ; Pusztai, Lajos ; Buisseret, Laurence ; Shi, Leming ; Shi-Wei, Liu ; Molinero, Luciana ; Estrada, M Valeria ; van Seijen, Maartje ; Lacroix-Triki, Magali ; Cheang, Maggie C U ; Bakir, Maise Al ; van de Vijver, Marc ; Dieci, Maria Vittoria ; Rebelatto, Marlon C ; Piccart, Martine ; Goetz, Matthew P ; Preusser, Matthias ; Sanders, Melinda E ; Regan, Meredith M ; Christie, Michael ; Misialek, Michael ; Ignatiadis, Michail ; de Maaker, Michiel ; van Bockstal, Mieke ; Castillo, Miluska ; Harbeck, Nadia ; Tung, Nadine ; Laudus, Nele ; Sirtaine, Nicolas ; Burchardi, Nicole ; Ternes, Nils ; Radosevic-Robin, Nina ; Gluz, Oleg ; Grimm, Oliver ; Nuciforo, Paolo ; NUCIFORO, PAOLO GIOVANNI; Jelinic, Petar ; Watson, Peter H ; Francis, Prudence A ; Russell, Prudence A ; Pierce, Robert H ; Hills, Robert ; Leon-Ferre, Roberto ; de Wind, Roland ; Shui, Ruohong ; Declercq, Sabine ; Leung, Sam ; Tabbarah, Sami ; Souza, Sandra C ; O’Toole, Sandra ; Swain, Sandra ; Willis, Scooter ; Ely, Scott ; Kim, Seong- Rim ; Bedri, Shahinaz ; Irshad, Sheeba ; Liu, Shi-Wei ; Hendry, Shona ; Bianchi, Simonetta ; Bragança, Sofia ; Paik, Soonmyung ; Fox, Stephen B ; Luen, Stephen J ; Naber, Stephen ; Luz, Sua ; Fineberg, Susan ; Soler, Teresa ; Gevaert, Thomas ; d’Alfons, Timothy ; John, Tom ; Sugie, Tomohagu ; Bossuyt, Veerle ; Manem, Venkata ; Cámaea, Vincente Peg ; Tong, Weida ; Yang, Wentao ; Tran, William T ; Wang, Yihong ; Allory, Yves ; Husain, Zaheed ; Husain Z. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.  NPJ breast cancer. 2020 January. 10.1038/s41523-020-0154-2
  • Brasó-Maristany, Fara ; Griguolo, Gaia ; Pascual, Tomás ; Paré, Laia ; NUCIFORO, PAOLO GIOVANNI; Llombart-Cussac, Antonio ; Bermejo, Begoña ; ANTUNES DE MELO E OLIVEIRA, MAFALDA; Morales, Serafín ; Martínez, Noelia ; VIDAL LOSADA, Mª JESUS; Adamo, Barbara ; Martínez, Olga ; Pernas, Sonia ; López, Rafael ; Muñoz, Montserrat ; Chic, Núria ; Galván, Patricia ; Garau, Isabel ; Manso, Luis ; Alarcón, Jesús ; Martínez, Eduardo ; Gregorio, Sara ; Gomis, Roger R ; Villagrasa, Patricia ; CORTES CASTAN, JAVIER; Ciruelos, Eva ; Prat, Aleix. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. NATURE COMMUNICATIONS. 2020 January. 10.1038/s41467-019-14111-3
  • Di Cosimo, Serena ; Appierto, Valentina ; Pizzamiglio, Sara ; Silvestri, Marco ; Baselga, José ; Piccart, Martine ; Huober, Jens ; Izquierdo, Miguel ; de la Pena, Lorena ; Hilbers, Florentine S ; de Azambuja, Evandro ; Untch, Michael ; Pusztai, Lajos ; Pritchard, Kathleen ; NUCIFORO, PAOLO GIOVANNI; Vincent-Salomon, Anne ; Symmans, Fraser ; Apolone, Giovanni ; de Braud, Filippo G ; Iorio, Marilena V ; Verderio, Paolo ; Daidone, Maria Grazia. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020 February. 10.3390/ijms21041386
  • De Angelis, Carmine; Nagi, Chandandeep ; Hoyt, Cliff C ; Liu, Linying ; Roman, Kristin ; Wang, Chichung ; Zheng, Yi ; Veeraraghavan, Jamunarani ; Sethunath, Vidyalakshmi ; NUCIFORO, PAOLO GIOVANNI; Wang, Tao ; Tsimelzon, Anna ; Mao, Sufeng ; Hilsenbeck, Susan G ; Trivedi, Meghana V ; Cataldo, Maria Letizia ; Pavlick, Anne ; Wolff, Antonio C ; Weigelt, Britta ; Reis-Filho, Jorge S ; Prat, Aleix ; Gutierrez, Carolina ; Osborne, Charles Kent ; Rimawi, Mothaffar F ; Schiff, Rachel. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without CLINICAL CANCER RESEARCH. 2020 February. 10.1158/1078-0432.CCR-19-1402
  • CAPDEVILA CASTILLON, JAUME; ARQUES CASAMITJANA, ORIOL; Hernandez Mora, Jose Ramon ; MATITO ARIZA, JUDIT; CARATU, GINEVRA; MANCUSO, FRANCESCO MATTIA; Landolfi, Stefania ; Barriuso, Jorge ; Jimenez-Fonseca, Paula ; Lopez Lopez, Carlos ; Garcia-Carbonero, Rocio ; Hernando, Jorge ; MATOS GARCIA, IGNACIO; NUCIFORO, PAOLO GIOVANNI; Hernández-Losa, Javier ; Esteller, Manel ; Martínez-Cardús, Anna ; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; GARCIA PALMER, HECTOR. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. CLINICAL CANCER RESEARCH. 2020 February. 10.1158/1078-0432.CCR-19-1266
  • GARCIA VALVERDE, LUIS ALFONSO; Rosell, Jordi; Serna, Garazi ; VALVERDE MORALES, CLAUDIA M; CARLES GALCERAN, JOAN; NUCIFORO, PAOLO GIOVANNI; Fletcher, Jonathan A ; ARRIBAS LOPEZ, JOAQUIN VICENTE; Politz, Oliver ; SERRANO GARCIA, CESAR. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. MOLECULAR CANCER THERAPEUTICS. 2020 June. 1158/1535-7163.MCT-19-1069
  • Tamborero, David ; DIENSTMANN, RODRIGO; Rachid, Maan Haj ; Boekel, Jorrit ; Baird, Richard ; BRAÑA GARCIA, IRENE; De Petris, Luigi ; Yachnin, Jeffrey ; Massard, Christophe ; Opdam, Frans L ; Schlenk, Richard ; Vernieri, Claudio ; GARRALDA CABANAS, ELENA; Masucci, Michele ; VILLALOBOS ALBERU, XENIA; CHAVARRIA MIRAS, ELENA; Cancer Core Europe consortium ; Calvo, Fabien ; Fröhling, Stefan ; Eggermont, Alexander ; Apolone, Giovanni ; Voest, Emile E ; Caldas, Carlos ; TABERNERO CATURLA, JOSEP; Ernberg, Ingemar ; RODON AHNERT, JORDI; Lehtiö, Janne ; Anand, Shubha ; AZARO, ANALIA BEATRIZ; Baars, Danny ; Bajalica-Lagercrantz, Svetlana ; BALMAÑA GELPI, JUDITH; Bergh, Jonas ; Bierkens, Mariska ; Blomqvist, Lennart ; Doherty, Gary J ; Forest, Arnauld ; Fornerone, Valentina ; Funingana, Ionut Gabriel ; Gabaldi, Paola ; Hartman, Johan ; Horak, Peter ; Karlsson, Claes ; Kasanicki, Mary ; Kreutzfeldt, Simon ; Lewensohn, Rolf ; Lindberg, Johan ; Lopez, Carlos ; Lundqvist, Andreas ; Martin-Romano, Patricia ; Martin, Jose-Ezequiel ; Meijer, Gerrit ; Muñoz, Susana ; Camus, Maud Ngo ; Nicotra, Claudio ; NUCIFORO, PAOLO GIOVANNI; Oberrauch, Petra ; Östling, Päivi ; PIRIS GIMENEZ, ALEJANDRO; Provenzano, Elena ; Rouleau, Etienne ; Rowell, John ; SAAVEDRA SANTAGADEA, OMAR; Valdivia, Ignacio Sánchez ; Scoazec, Giovanni ; Seamon, Kenneth ; Tischkowitz, Marc ; van der Kolk, Lizet ; van der Noll, Ruud ; Vis, Daniel ; VIVANCOS PRELLEZO, ANA; von Gertten, Christina ; Wennborg, Anders ; Wessels, Lodewyk ; Wirta, Valtteri ; Wolfart, Julia. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. NATURE MEDICINE. 2020 July. 10.1038/s41591-020-0969-2
  • GRIS OLIVER, ALBERT; PALAFOX SANCHEZ, MARTA; MONTSERRAT VICENTE, LAIA; Brasó-Maristany, Fara ; Òdena, Andreu ; SANCHEZ GUIXE, MONICA; IBRAHIM, YASIR HUSSEIN; VILLACAMPA JAVIERRE, GUILLERMO; GRUESO GRAGERA, JUDIT; Parés, Mireia ; GUZMAN, MARTA; RODRIGUEZ FERREIRO, OLGA; Bruna, Alejandra ; Hirst, Caroline S ; Barnicle, Alan ; de Bruin, Elza C ; Reddy, Avinash ; Schiavon, Gaia ; ARRIBAS LOPEZ, JOAQUIN VICENTE; Mills, Gordon B ; Caldas, Carlos ; Dienstman, Rodrigo ; PRAT APARICIO, ALEIX; NUCIFORO, PAOLO GIOVANNI; Razavi, Pedram ; SCALTRITI, MAURIZIO; Turner, Nicholas C ; SAURA MANICH, CRISTINA; Davies, Barry R ; Oliveira, Mafalda ; SERRA ELIZALDE, VIOLETA. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. CLINICAL CANCER RESEARCH. 1158/1078-0432.CCR-19-3324
  • Lupo, Barbara ; Sassi, Francesco ; Pinnelli, Marika ; Galimi, Francesco ; Zanella, Eugenia R ; Vurchio, Valentina ; Migliardi, Giorgia ; Gagliardi, Paolo Armando ; Puliafito, Alberto ; Manganaro, Daria ; Luraghi, Paolo ; Kragh, Michael ; Pedersen, Mikkel W ; Horak, Ivan D ; Boccaccio, Carla ; Medico, Enzo ; Primo, Luca ; Nichol, Daniel ; Spiteri, Inmaculada ; Heide, Timon ; Vatsiou, Alexandra ; Graham, Trevor A ; ELEZ FERNANDEZ, MARIA ELENA; ARGILES MARTINEZ, GUILLERMO; NUCIFORO, PAOLO GIOVANNI; Sottoriva, Andrea ; DIENSTMANN, RODRIGO; Pasini, Diego ; Grassi, Elena ; Isella, Claudio ; Bertotti, Andrea ; Trusolino, Livio. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. SCIENCE TRANSLATIONAL MEDICINE. 2020 August. 10.1126/scitranslmed.aax8313
  • Ciruelos, Eva M ; Villagrasa, Patricia ; Pascual, Tomás ; Oliveira, Mafalda ; Pernas, Sonia ; Paré, Laia ; ESCRIVA DE ROMANI MUÑOZ, SANTIAGO; Manso, Luis ; Adamo, Barbara ; Martínez de Dueñas, Eduardo ; CORTES CASTAN, JAVIER; Vázquez, Silvia ; Perelló, Antonia ; Garau, Isabel ; Melé, Mireia ; Martínez Jañez, Noelia ; Montaño, Alvaro ; Bermejo, Begoña ; Morales, Serafín ; Echarri, Mª Jose ; Vega, Estela ; González-Farré, Blanca ; Martínez, Débora ; GALVAN JURADO, PATRICIA; Canes, Jordi ; NUCIFORO, PAOLO GIOVANNI; Gonzàlez Farré, Xavier ; Prat, Aleix. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. CLINICAL CANCER RESEARCH. 2020 November. 1158/1078-0432.CCR-20-0844
  • Zunder, Stéphanie M ; PEREZ LOPEZ, RAQUEL; de Kok, Bente M ; Raciti, Maria Vittoria ; van Pelt, Gabi W ; DIENSTMANN, RODRIGO; Garcia-Ruiz, Alonso ; Meijer, C Arnoud ; Gelderblom, Hans ; Tollenaar, Rob A ; NUCIFORO, PAOLO GIOVANNI; Wasser, Martin N ; Mesker, Wilma E. Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. EUROPEAN JOURNAL OF RADIOLOGY. 2020 December. 10.1016/j.ejrad.2020.109345
  • Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez E, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P. Sci Rep. 2019 Sep 19;9(1):13568.
  • Early evolutionary divergence between papillary and anaplastic thyroid cancers. Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Ann Oncol. 2019 Nov 1;30(11):1843.
  • Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Mol Oncol. 2019 Sep;13(9):1827-1835.
  • Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, Alvarez M, Parrado MRC, García-Barberán V, Diaz-Rubio E. Sci Rep. 2019 Jun 20;9(1):8976.
  • Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. ESMO Open. 2019 Mar 8;4(2):e000444.
  • Vivancos A, Élez E, Salazar R. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime? Ann Oncol.29: 532-534.
  • Capdevila J, Mayor R; Mancuso FF, Iglesias C; Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez C, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol.29: 1454-1460.
  • Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst. 110: 914-917.
  • Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest. 128: 3887-3905.
  • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN; Kristel P, de Bustos L, Guzman M, Rodriguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O; O’Connor MJ, Balmaña J, Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 29: 1203-1210.
  • Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, Lopez-Bigas N, Ramón Y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. Clin Cancer Res. 24: 2812-2819.
  • Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel J M, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer H G, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017 Oct 1;28(10):2451-2457.
  • García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, Tabernero J, Vivancos A. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. 2017 Dec 1;28(12):2943-2949.
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017 Sep;11(9):1263-1272.
  • Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017 Jun 1;28(6):1294-1301.
  • Pérez-Alea M, Vivancos A, Caratú G, Matito J, Ferrer B, Hernandez-Losa J, Cortés J, Muñoz E, Garcia-Patos V, Recio JA. Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget. 2016 May 10;7(19):28086-95. doi: 10.18632/oncotarget.8578.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081.
  • Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.
  • Alves-Rodrigues I, Ferreira PG, Moldón A, Vivancos AP, Hidalgo E, Guigó R, Ayté J. Spatiotemporal Control of Forkhead Binding to DNA Regulates the Meiotic Gene Expression Program. Cell Rep. 2016 Feb 2;14(4):885-95. doi: 10.1016/j.celrep.2015.12.074.
  • Vivancos A, Caratú G, Matito J, Muñoz E, Ferrer B, Hernández-Losa J, Bodet D, Pérez-Alea M, Cortés J, Garcia-Patos V, Recio JA. Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell Melanoma Res. 2016 Mar;29(2):247-53. doi: 10.1111/pcmr.12452.
  • Yus E, Güell M, Vivancos AP, Chen WH, Lluch-Senar M, Delgado J, Gavin AC, Bork P, Serrano L. Transcription start site associated RNAs in bacteria. Mol. Syst. Biol. 2012; 8: 585
  • Esteve-Codina A, Kofler R, Himmelbauer H, Ferretti L, Vivancos AP, Groenen MA, Folch JM, Rodríguez MC, Pérez-Enciso M. Partial short-read sequencing of a highly inbred Iberian pig and genomics inference thereof. Heredity (Edinb) 2011 Sep; 107(3): 256-64
  • Zuin A, Carmona M, Morales-Ivorra I, Gabrielli N, Vivancos AP, Ayté J, Hidalgo E. Lifespan extension by calorie restriction relies on the Sty1 MAP kinase stress pathway. EMBO J. 2010 Mar; 29(5): 981-91
  • Vivancos AP, Castillo EA, Biteau B, Nicot C, Ayté J, Toledano MB, Hidalgo E. A cysteine-sulfinic acid in peroxiredoxin regulates H2O2-sensing by the antioxidant Pap1 pathway. Proc. Natl. Acad. Sci. U.S.A. 2005 Jun; 102(25): 8875-80
  • Vivancos AP, Castillo EA, Jones N, Ayté J, Hidalgo E. Activation of the redox sensor Pap1 by hydrogen peroxide requires modulation of the intracellular oxidant concentration. Mol. Microbiol. 2004 Jun; 52(5): 1427-35
  • Castillo EA, Vivancos AP, Jones N, Ayté J, Hidalgo E. Schizosaccharomyces pombe cells lacking the Ran-binding protein Hba1 show a multidrug resistance phenotype due to constitutive nuclear accumulation of Pap1. J. Biol. Chem. 2003 Oct; 278(42): 40565-72

Projects

  • FUSOMAP: Development of microbiota-based diagnostic and prognostic models by mapping intratumoral Fusobacterium and associated gut microbiota in early-stage colorectal cancer – Mutua Madrileña and ISCIII.
  • Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions – COLOSSUS, H2020.
  • Opportunity: To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer – OPTIMISTICC, Grand Challenge, Cancer Research UK.
  • Microbiota composition as risk predictor in cancer patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – La Marató TV3, 2021.
  • Development and validation of Fusobacterium and its associated microbiota as risk stratification biomarker after SoC treatment in locally advanced rectal cancer. Agencia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). 1/02/2024-31/07/2025. PI: Paolo Nuciforo

Related News

Researchers discover the mechanism by which tumor cells become resistant to chemotherapy in colorectal cancer

A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some…

21 Feb 2023
Multiparametric magnetic resonance imaging as a non-invasive predictor of response to immune checkpoint inhibitors

Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…

21 Oct 2023
Proof-of-concept study points to the placenta as a protective barrier against COVID-19 during pregnancy

Findings from a comprehensive clinical, morphological, and molecular analysis of a cohort of 37 pregnant women with and without SARS-CoV-2…

18 Feb 2021
Cancer Grand Challenges’ annual celebration of scientific progress: the OPTIMISTICC team story and taking on the microbiota challenge

Founded by Cancer Research UK (CRUK) and the National Cancer Institute (NIH-NCI, USA) the Cancer Grand Challenges are internationally funded…

25 Jul 2022
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required